Your Patients Can't Find Their Medication — Here's How You Can Help

Parkinson's disease patients depend on consistent access to Carbidopa/Levodopa XR to maintain motor function and quality of life. But with the ongoing shortage of extended-release tablets, many of your patients are calling your office in distress, unable to fill their prescriptions.

As a provider, you're in a unique position to help. This guide outlines the current availability landscape, explains why patients are struggling, and provides five actionable steps your practice can take — along with alternative treatment options and workflow tips to streamline the process.

Current Availability of Carbidopa/Levodopa XR

As of early 2026, Carbidopa/Levodopa extended-release tablets remain on the ASHP drug shortage list. The shortage primarily affects the generic ER tablets (25/100 mg and 50/200 mg strengths) produced by a limited number of manufacturers including Accord and Sun Pharma.

Key availability facts:

• Generic ER tablets: Intermittently available. Supply varies by wholesaler, region, and pharmacy
• Generic IR tablets: Widely available — not affected by the same shortage
• Rytary (brand ER capsules): Available but requires prior authorization and costs $800-$1,500/month without insurance
• Stalevo (generic Carbidopa/Levodopa/Entacapone): Generally available at $54-$100/month with coupons

For the latest shortage details, see our provider briefing on the Carbidopa/Levodopa XR shortage.

Why Your Patients Can't Find It

Understanding the root causes helps you set appropriate expectations with patients:

Concentrated Manufacturing Base

With Sinemet CR discontinued, the entire ER tablet supply depends on a handful of generic manufacturers. Any production disruption at even one facility creates nationwide ripple effects.

Allocation-Based Distribution

During shortages, wholesalers allocate limited supply across their pharmacy customers based on historical ordering patterns. New patients or pharmacies that haven't regularly stocked the medication may receive little to no allocation.

Chain Pharmacy Constraints

Large pharmacy chains often have centralized purchasing systems with limited flexibility during shortages. Independent pharmacies, with access to multiple wholesalers, may have more success sourcing the medication.

Patient Behavior Patterns

Some patients wait until they're nearly out of medication before trying to refill, leaving no buffer time to search for stock. Others may not know about tools that can help them locate available supply.

What Providers Can Do: 5 Actionable Steps

Step 1: Direct Patients to Pharmacy Stock Tools

The single most impactful thing you can do is equip patients with tools to find their own medication. Medfinder for Providers lets you (and your patients) search for Carbidopa/Levodopa XR availability by zip code. Consider:

• Adding the Medfinder link to your practice's patient resource handouts
• Having your front desk or care coordinators help patients check availability during office visits
• Including the link in follow-up communications when prescribing Carbidopa/Levodopa XR

You can also share this patient-facing guide: How to find Carbidopa/Levodopa XR in stock near you.

Step 2: Prescribe With Flexibility

When writing prescriptions for Carbidopa/Levodopa ER during a shortage, consider these strategies:

• Allow generic substitution across manufacturers — don't specify a single manufacturer unless medically necessary
• Send prescriptions to pharmacies with confirmed stock rather than the patient's usual pharmacy
• Consider writing for 90-day supplies when possible, reducing the number of fill attempts needed
• Document backup alternatives in the patient's chart so quick switches can happen if the ER tablets become unavailable

Step 3: Have a Conversion Plan Ready

For patients who cannot find the ER tablets, have a pre-calculated conversion ready in the chart. Key conversion considerations:

• ER → IR conversion: ER has ~70-75% bioavailability vs. IR. Increase dosing frequency to 3-4 times daily. Start conservatively and titrate up based on symptom control.
• ER → Rytary conversion: Follow the Rytary prescribing information conversion table. Note that Rytary doses are not mg-for-mg equivalent.
• ER → Stalevo consideration: Adding Entacapone to IR Carbidopa/Levodopa can extend the duration of each dose, partially mimicking the ER effect.

For more details on alternatives, see alternatives to Carbidopa/Levodopa XR.

Step 4: Educate Patients on Proactive Refill Habits

Many treatment gaps are preventable with better refill timing. Coach patients to:

• Refill prescriptions 7-10 days before running out
• Keep a 2-week medication buffer whenever possible
• Set phone reminders for refill dates
• Ask their pharmacy to place them on a notification list for when stock arrives

Step 5: Connect Patients With Financial Assistance

Cost barriers can compound availability issues. Help patients access savings:

• Discount coupons: GoodRx, SingleCare, and other coupon programs can reduce generic ER costs to $29-$40/month
• Rytary savings card: Through PhilRx, commercially insured patients may pay as little as $0-$20/month
• Patient assistance programs: NeedyMeds (needymeds.org), RxAssist (rxassist.org), and the Parkinson's Foundation offer resources for patients with financial hardship

For a comprehensive cost guide to share with patients, see how to save money on Carbidopa/Levodopa XR. For provider-specific guidance on cost strategies, see our provider's guide to helping patients save money on Carbidopa/Levodopa XR.

Alternative Medications at a Glance

Quick reference for when you need to switch a patient off the ER tablets:

• Carbidopa/Levodopa IR: Same active ingredients, more frequent dosing. Widely available. $9-$15/month with coupon. First-line substitute.
• Rytary: Brand ER capsules with dual-release mechanism. Smoother levels but expensive. Prior auth required. $800-$1,500/month cash.
• Stalevo (Carbidopa/Levodopa/Entacapone): Extends Levodopa duration via COMT inhibition. Good for wearing-off symptoms. $54-$100/month generic.
• Pramipexole/Ropinirole: Dopamine agonists for adjunct use. Not equivalent to Levodopa monotherapy. $10-$30/month generic. Higher impulse control disorder risk.

Workflow Tips for Your Practice

Integrating shortage management into your practice workflow can save time and reduce patient distress:

• Create a shortage alert protocol: When a commonly prescribed medication enters shortage, flag affected patients in your EHR for proactive outreach
• Template notes: Create pre-built conversion order sets for Carbidopa/Levodopa ER → IR and ER → Rytary so transitions can happen quickly
• Designate a point person: Having one staff member (nurse, MA, or care coordinator) monitor shortage updates and coordinate with pharmacies saves provider time
• Batch communications: Send a patient-facing notification (letter, portal message, or email) to all affected patients explaining the shortage and providing resources
• Bookmark key resources: Medfinder for Providers, the ASHP shortage database, and manufacturer contact numbers

Final Thoughts

The Carbidopa/Levodopa XR shortage creates real risk for your Parkinson's patients — treatment gaps can lead to rapid symptom deterioration and potentially dangerous withdrawal effects. But with proactive planning, flexible prescribing, and the right tools, you can help your patients maintain continuity of care.

Start by directing patients to Medfinder to find pharmacies with stock. Have conversion plans ready in the chart. And stay informed on shortage updates so you can get ahead of supply disruptions before your patients are affected.

For the latest shortage information, see our provider briefing on the Carbidopa/Levodopa XR shortage in 2026.